The uPA/PAI-1 assay and the EPClin® test are useful tools that add to clinico-anatomical characteristics to determine the indication of adjuvant chemotherapy in case of intermediate-prognosis invasive breast cancer. The principal purpose of our study was to analyze the concordance of uPA/PAI-1 and EPClin® in classification of patients into two groups: low and high risk of relapse.
We prospectively included 63 patients treated for intermediate-prognosis invasive breast cancer. All of these patients received a uPA/PAI-1 assay and an EPClin® test.
The uPA/PAI-1 assay and EPClin® test were consistent for 56.2 % and inconsistent for 43.8 %. In the event of a discrepancy, the treatment decision was based in 95.2 % of patients on the EPClin® test result. In total, 38 patients were selected for adjuvant chemotherapy after achievement of the two tests. The mean time to report results after surgery was 9 days for the uPA/PAI-1 assay and 35 days for the EPClin® test. No cases of recurrence or death were found, with an average follow-up of 32 months.
The EPClin® test resulted in more chemotherapy prescriptions than indicated by uPA/PAI-1. However, we can’t conclude to the superiority of one of these two tests, survival data and the effective of our study being insufficient. In general, studies comparing different signatures useful to the therapeutic decision of intermediate prognosis breast cancers should be encouraged.

Copyright © 2021. Published by Elsevier Masson SAS.

Author